RU2016112266A - Ингибитор PI3K для лечения респираторного заболевания - Google Patents
Ингибитор PI3K для лечения респираторного заболевания Download PDFInfo
- Publication number
- RU2016112266A RU2016112266A RU2016112266A RU2016112266A RU2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A RU 2016112266 A RU2016112266 A RU 2016112266A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- use according
- infection
- respiratory
- patient
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 206010057190 Respiratory tract infections Diseases 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- NLUPPCTVKHDVIQ-GASCZTMLSA-N n-[5-[4-[5-[[(2r,6s)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1h-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=NC=C1C1=CC(C=2OC(CN3C[C@@H](C)O[C@@H](C)C3)=CN=2)=C(C=NN2)C2=C1 NLUPPCTVKHDVIQ-GASCZTMLSA-N 0.000 claims 2
- 208000037920 primary disease Diseases 0.000 claims 2
- -1 1H-indol-4-yl Chemical group 0.000 claims 1
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201318415A GB201318415D0 (en) | 2013-10-17 | 2013-10-17 | Novel use |
| GB1318415.5 | 2013-10-17 | ||
| GB201319828A GB201319828D0 (en) | 2013-11-11 | 2013-11-11 | Novel use |
| GB1319828.8 | 2013-11-11 | ||
| GB201409018A GB201409018D0 (en) | 2014-05-21 | 2014-05-21 | Novel use |
| GB1409018.7 | 2014-05-21 | ||
| PCT/EP2014/072074 WO2015055691A1 (en) | 2013-10-17 | 2014-10-15 | Pi3k inhibitor for treatment of respiratory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016112266A true RU2016112266A (ru) | 2017-11-20 |
Family
ID=51842492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016112266A RU2016112266A (ru) | 2013-10-17 | 2014-10-15 | Ингибитор PI3K для лечения респираторного заболевания |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160263109A1 (enExample) |
| EP (1) | EP3057588A1 (enExample) |
| JP (1) | JP6475707B2 (enExample) |
| KR (1) | KR20160062178A (enExample) |
| CN (1) | CN105611929A (enExample) |
| AU (2) | AU2014336251A1 (enExample) |
| CA (1) | CA2925064A1 (enExample) |
| RU (1) | RU2016112266A (enExample) |
| WO (1) | WO2015055691A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201509492D0 (en) | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
| CN111773219A (zh) * | 2020-08-11 | 2020-10-16 | 王思慧 | Pi3k抑制剂nvp-byl719在制备新型冠状病毒抑制剂中的应用 |
| KR102672515B1 (ko) | 2022-04-07 | 2024-06-04 | 한양대학교 에리카산학협력단 | 레일 로봇 및 레일 로봇 시스템 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9301943A (es) | 1992-04-02 | 1994-08-31 | Smithkline Beecham Corp | Compuestos. |
| BR9604976A (pt) | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Inalador de dose medida sistema inalador de dose medida e uso do mesmo |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| CA2323771A1 (en) | 1998-03-14 | 1999-09-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| SI1305329T2 (sl) | 2000-08-05 | 2015-07-31 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
| CA2445839A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| JP2005500290A (ja) | 2001-06-12 | 2005-01-06 | グラクソ グループ リミテッド | 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル |
| BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE60318188T2 (de) | 2002-03-26 | 2008-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| WO2003091204A1 (en) | 2002-04-25 | 2003-11-06 | Glaxo Group Limited | Phenethanolamine derivatives |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| WO2004018429A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| US20060089375A1 (en) | 2002-09-16 | 2006-04-27 | Allen David G | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| CA2499150A1 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| RU2332400C2 (ru) | 2002-10-28 | 2008-08-27 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| KR20080065318A (ko) | 2003-10-14 | 2008-07-11 | 글락소 그룹 리미티드 | 무스카린성 아세틸콜린 수용체 길항제 |
| CN102028994B (zh) | 2003-11-03 | 2013-04-24 | 葛兰素集团有限公司 | 流体分配装置 |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| US20070111995A1 (en) | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
| EP1735314A1 (en) | 2004-03-16 | 2006-12-27 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
| GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| PE20060259A1 (es) | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| RU2391338C2 (ru) | 2004-10-19 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные хинолина |
| WO2006072599A2 (en) | 2005-01-10 | 2006-07-13 | Glaxo Group Limited | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| GB0612630D0 (en) * | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
| JPWO2009128520A1 (ja) * | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する複素環化合物 |
| MY160454A (en) * | 2009-04-30 | 2017-03-15 | Glaxo Group Ltd | Oxazole substituted indazoles as pi3-kinase inhibitors |
| DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
| US9326987B2 (en) * | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| GB201018124D0 (en) * | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
-
2014
- 2014-10-15 AU AU2014336251A patent/AU2014336251A1/en not_active Abandoned
- 2014-10-15 US US15/028,973 patent/US20160263109A1/en not_active Abandoned
- 2014-10-15 CA CA2925064A patent/CA2925064A1/en not_active Abandoned
- 2014-10-15 KR KR1020167012679A patent/KR20160062178A/ko not_active Withdrawn
- 2014-10-15 EP EP14790537.6A patent/EP3057588A1/en not_active Withdrawn
- 2014-10-15 JP JP2016523933A patent/JP6475707B2/ja not_active Expired - Fee Related
- 2014-10-15 WO PCT/EP2014/072074 patent/WO2015055691A1/en not_active Ceased
- 2014-10-15 RU RU2016112266A patent/RU2016112266A/ru not_active Application Discontinuation
- 2014-10-15 CN CN201480056821.5A patent/CN105611929A/zh active Pending
-
2017
- 2017-09-08 AU AU2017225139A patent/AU2017225139A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6475707B2 (ja) | 2019-02-27 |
| KR20160062178A (ko) | 2016-06-01 |
| EP3057588A1 (en) | 2016-08-24 |
| JP2016533367A (ja) | 2016-10-27 |
| WO2015055691A1 (en) | 2015-04-23 |
| CA2925064A1 (en) | 2015-04-23 |
| AU2017225139A1 (en) | 2017-10-05 |
| US20160263109A1 (en) | 2016-09-15 |
| CN105611929A (zh) | 2016-05-25 |
| AU2014336251A1 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| JP2014530900A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| JP2016532673A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| RU2008143457A (ru) | Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы | |
| JP2014513110A5 (enExample) | ||
| JP2016515562A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2005517006A5 (enExample) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2009515814A5 (enExample) | ||
| IL225704A0 (en) | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1 h-Indazole as pi3k inhibitors for use in the treatment of respiratory problems | |
| JP2016503785A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| JP2016522254A5 (enExample) | ||
| RU2016112266A (ru) | Ингибитор PI3K для лечения респираторного заболевания | |
| JP2013544854A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| RU2015137972A (ru) | Новые производные дигидрохинолин-2-она в качестве ингибиторов альдостеронсинтазы (cyp1 1 b2 или cyp1 1 b1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20171016 |